• # LGM Pharma is a Epothilone B CAS# 152044-54-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Epothilone B
  • CAS #: 152044-54-7
  • Mode of Action:

    The principal mechanism of the epothilone class is inhibition of microtubule function. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Epothilone B possess the same biological effects as taxol both in vitro and in cultured cells. This is because they share the same binding site, as well as binding affinity to the microtubule. Like taxol, epothilone B binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules. Furthermore, epothilone B has also been shown to induce tubulin polymerization into microtubules without the presence of GTP. This is caused by formation of microtubule bundles throughout the cytoplasm. Finally, epothilone B also causes cell cycle arrest at the G2-M transition phase, thus leading to cytotoxicity and eventually cell apoptosis.

  • IUPAC: (1S, 3S, 7R, 10S, 11R, 12S, 16S)-7, 11-dihydroxy-8, 8, 10, 12, 16-pentamethyl-3-[(1E)-1-(2-methyl-1, 3-thiazol-4-yl)prop-1-en-2-yl]-4, 17-dioxabicyclo[14.1.0]heptadecane-5, 9-dione
  • DrugBank: DB03010 (EXPT01349)
  • Formula: C27H41NO6S
  • Molecular Mass: 507.683
  • Synonyms: EPO 906, EPO906, patupilone
  • SMILES: C[C@H]1CCC[C@]2(C)O[C@H]2C[C@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@@H](C)[C@@H]1O)C(C)=CC1=CSC(C)=N1
  • InChl: 1S/C27H41NO6S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)33-23(30)13-21(29)26(5,6)25(32)17(3)24(15)31/h11,14-15,17,20-22,24,29,31H,8-10,12-13H2,1-7H3/b16-11+/t15-,17-,20-,21+,22-,24+,27-/m0/s1
  • General Reference:
    PubChem Compound: https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=46936553
    PubChem Substance: https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505629
    Therapeutic Targets Database: https://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000616
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service